MAHLY (Medipal Holdings) Tariff Resilience Score: 8/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAHLY Medipal Holdings Corp MAHLY
82 GF Score
Price $17.99
GF Value $16.38
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Medipal Holdings Tariff Resilience Score?

Medipal Holdings MAHLY 82 Tariff Resilience Score is 8 as of Jul. 15, 2026. GuruFocus rates MAHLY with a GF Score™ of 82/100 and a GF Value™ of $16.38 (Fairly Valued). The stock has 1 warning sign investors should review. Among 119 Medical Distribution companies, Medipal Holdings ranks better than 99.16% on this metric.

Medipal Holdings has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Medipal Holdings has Medipal's focus on pharmaceuticals and medical supplies, often exempt from tariffs, provides resilience. Its strong domestic market in Japan further reduces tariff exposure.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Medipal Holdings might have Highly Resilient.

Medipal Holdings  (OTCPK:MAHLY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Medipal Holdings Tariff Resilience Score Related Terms

MAHLY vs MCK, CAH, COR: Tariff Resilience Score Comparison

For the Medical Distribution subindustry, Medipal Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medipal Holdings Tariff Resilience Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Medipal Holdings's Tariff Resilience Score falls into.


MAHLY
82GF Score
Medipal Holdings Corp MAHLY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Medipal Holdings (MAHLY) has a Tariff Resilience Score of 8 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Medipal Holdings ranks #1 out of 119 companies in the Medical Distribution industry, placing it in the top 0.8%.
Is Medipal Holdings' Tariff Resilience Score too high?
Medipal Holdings' current Tariff Resilience Score is 8. Based on the distribution chart, Medipal Holdings ranks #1 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Medipal Holdings has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Tariff Resilience Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #1 out of 119 companies for Tariff Resilience Score. This places Medipal Holdings in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Distribution company?
A good Tariff Resilience Score depends on the Medical Distribution industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Medipal Holdings's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.38, compared to a current price of $17.99 — trading 9.8% above its estimated fair value. The current Tariff Resilience Score is 8. Medipal Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current Tariff Resilience Score is 8 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MAHLY) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued. The current stock price of $17.99 is trading 9.8% above its estimated GF Value™ of $16.38. GuruFocus considers Medipal Holdings to be Fairly Valued.

Key valuation signals for MAHLY:

  • Tariff Resilience Score: 8
  • GF Value™: $16.38 vs. price of $17.99 (9.8% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medipal Holdings Business Description

Other Exchanges MEPDF:USA7459:Japan
Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
82GF Score

Get the complete analysis for MAHLY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.99
Price
$16.38
GF Value